Tag Archives: Massachusetts Institute of Technology (MIT)

Tough colour and the flower beetle

The flower beetle Torynorrhina flammea. [downloaded from https://www.nanowerk.com/nanotechnology-news2/newsid=58269.php]

That is one gorgeous beetle and a June 17, 2021 news item on Nanowerk reveals that it features in a structural colour story (i.e, how structures rather than pigments create colour),

The unique mechanical and optical properties found in the exoskeleton of a humble Asian beetle has the potential to offer a fascinating new insight into how to develop new, effective bio-inspired technologies.

Pioneering new research by a team of international scientists, including Professor Pete Vukusic from the University of Exeter, has revealed a distinctive, and previously unknown property within the carapace of the flower beetle – a member of the scarab beetle family.

The study showed that the beetle has small micropillars within the carapace – or the upper section of the exoskeleton – that give the insect both strength and flexibility to withstand damage very effectively.

Crucially, these micropillars are incorporated into highly regular layering in the exoskeleton that concurrently give the beetle an intensely bright metallic colour appearance.

A June 18, 2021 University of Exeter press release (also on EurekAlert but published June 17, 2021), delves further into the researchers’ new insights,

For this new study, the scientists used sophisticated modelling techniques to determine which of the two functions – very high mechanical strength or conspicuously bright colour – were more important to the survival of the beetle.

They found that although these micropillars do create a highly enhanced toughness of the beetle shell, they were most beneficial for optimising the scattering of coloured light that generates its conspicuous appearance.

The research is published this week in the leading journal, Proceedings of the National Academy of Sciences, PNAS.

Professor Vukusic, one of three leads of the research along with Professor Li at Virginia Tech and Professor Kolle at MIT [Massachusetts Institute of Technology], said: “The astonishing insights generated by this research have only been possible through close collaborative work between Virginia Tech, MIT, Harvard and Exeter, in labs that trailblaze the fields of materials, mechanics and optics. Our follow-up venture to make use of these bio-inspired principles will be an even more exciting journey.”.

The seeds of the pioneering research were sown more than 16 years ago as part of a short project created by Professor Vukusic in the Exeter undergraduate Physics labs. Those early tests and measurements, made by enthusiastic undergraduate students, revealed the possibility of intriguing multifunctionality.

The original students examined the form and structure of beetles’ carapce to try to understand the simple origin of their colour. They noticed for the first time, however, the presence of strength-inducing micropillars.

Professor Vukusic ultimately carried these initial findings to collaborators Professor Ling Li at Virginia Tech and Professor Mathias Kolle at Harvard and then MIT who specialise in the materials sciences and applied optics. Using much more sophisticated measurement and modelling techniques, the combined research team were also to confirm the unique role played by the micropillars in enhancing the beetles’ strength and toughness without compromising its intense metallic colour.

The results from the study could also help inspire a new generation of bio-inspired materials, as well as the more traditional evolutionary research.

By understanding which of the functions provides the greater benefit to these beetles, scientists can develop new techniques to replicate and reproduce the exoskeleton structure, while ensuring that it has brilliant colour appearance with highly effective strength and toughness.

Professor Vukusic added: “Such natural systems as these never fail to impress with the way in which they perform, be it optical, mechanical or in another area of function. The way in which their optical or mechanical properties appear highly tolerant of all manner of imperfections too, continues to offer lessons to us about scientific and technological avenues we absolutely should explore. There is exciting science ahead of us on this journey.”

Here’s a link to and a citation for the paper,

Microstructural design for mechanical–optical multifunctionality in the exoskeleton of the flower beetle Torynorrhina flammea by Zian Jia, Matheus C. Fernandes, Zhifei Deng, Ting Yang, Qiuting Zhang, Alfie Lethbridge, Jie Yin, Jae-Hwang Lee, Lin Han, James C. Weaver, Katia Bertoldi, Joanna Aizenberg, Mathias Kolle, Pete Vukusic, and Ling Li. PNAS June 22, 2021 118 (25) e2101017118; DOI: https://doi.org/10.1073/pnas.2101017118

This paper is behind a paywall.

Carbon nanotubes can scavenge energy from environment to generate electricity

A June 7, 2021 news item on phys.org announces research into a new method for generating electricity (Note: A link has been removed),

MIT [Massachusetts Institute of Technology] engineers have discovered a new way of generating electricity using tiny carbon particles that can create a current simply by interacting with liquid surrounding them.

The liquid, an organic solvent, draws electrons out of the particles, generating a current that could be used to drive chemical reactions or to power micro- or nanoscale robots, the researchers say.

“This mechanism is new, and this way of generating energy is completely new,” says Michael Strano, the Carbon P. Dubbs Professor of Chemical Engineering at MIT. “This technology is intriguing because all you have to do is flow a solvent through a bed of these particles. This allows you to do electrochemistry, but with no wires.”

A June 7, 2021 MIT news release (also on EurekAlert), which generated the news item, delves further into the research,

In a new study describing this phenomenon, the researchers showed that they could use this electric current to drive a reaction known as alcohol oxidation — an organic chemical reaction that is important in the chemical industry.

Strano is the senior author of the paper, which appears today [June 7, 2021] in Nature Communications. The lead authors of the study are MIT graduate student Albert Tianxiang Liu and former MIT researcher Yuichiro Kunai. Other authors include former graduate student Anton Cottrill, postdocs Amir Kaplan and Hyunah Kim, graduate student Ge Zhang, and recent MIT graduates Rafid Mollah and Yannick Eatmon.

Unique properties

The new discovery grew out of Strano’s research on carbon nanotubes — hollow tubes made of a lattice of carbon atoms, which have unique electrical properties. In 2010, Strano demonstrated, for the first time, that carbon nanotubes can generate “thermopower waves.” When a carbon nanotube is coated with layer of fuel, moving pulses of heat, or thermopower waves, travel along the tube, creating an electrical current.

That work led Strano and his students to uncover a related feature of carbon nanotubes. They found that when part of a nanotube is coated with a Teflon-like polymer, it creates an asymmetry that makes it possible for electrons to flow from the coated to the uncoated part of the tube, generating an electrical current. Those electrons can be drawn out by submerging the particles in a solvent that is hungry for electrons.

To harness this special capability, the researchers created electricity-generating particles by grinding up carbon nanotubes and forming them into a sheet of paper-like material. One side of each sheet was coated with a Teflon-like polymer, and the researchers then cut out small particles, which can be any shape or size. For this study, they made particles that were 250 microns by 250 microns.

When these particles are submerged in an organic solvent such as acetonitrile, the solvent adheres to the uncoated surface of the particles and begins pulling electrons out of them.

“The solvent takes electrons away, and the system tries to equilibrate by moving electrons,” Strano says. “There’s no sophisticated battery chemistry inside. It’s just a particle and you put it into solvent and it starts generating an electric field.”

Particle power

The current version of the particles can generate about 0.7 volts of electricity per particle. In this study, the researchers also showed that they can form arrays of hundreds of particles in a small test tube. This “packed bed” reactor generates enough energy to power a chemical reaction called an alcohol oxidation, in which an alcohol is converted to an aldehyde or a ketone. Usually, this reaction is not performed using electrochemistry because it would require too much external current.

“Because the packed bed reactor is compact, it has more flexibility in terms of applications than a large electrochemical reactor,” Zhang says. “The particles can be made very small, and they don’t require any external wires in order to drive the electrochemical reaction.”

In future work, Strano hopes to use this kind of energy generation to build polymers using only carbon dioxide as a starting material. In a related project, he has already created polymers that can regenerate themselves using carbon dioxide as a building material, in a process powered by solar energy. This work is inspired by carbon fixation, the set of chemical reactions that plants use to build sugars from carbon dioxide, using energy from the sun.

In the longer term, this approach could also be used to power micro- or nanoscale robots. Strano’s lab has already begun building robots at that scale, which could one day be used as diagnostic or environmental sensors. The idea of being able to scavenge energy from the environment to power these kinds of robots is appealing, he says.

“It means you don’t have to put the energy storage on board,” he says. “What we like about this mechanism is that you can take the energy, at least in part, from the environment.”

Here’s a link to and a citation for the paper,

Solvent-induced electrochemistry at an electrically asymmetric carbon Janus particle by Albert Tianxiang Liu, Yuichiro Kunai, Anton L. Cottrill, Amir Kaplan, Ge Zhang, Hyunah Kim, Rafid S. Mollah, Yannick L. Eatmon & Michael S. Strano. Nature Communications volume 12, Article number: 3415 (2021) DOI: https://doi.org/10.1038/s41467-021-23038-7Published 07 June 2021

This paper is open access.

Follow up to the Charles M. Lieber affair and US government efforts to prosecute nanotech scientists

Rebecca Trager in a March 5, 2021 news article for Chemistry World highlights support for Charles M. Lieber (Harvard professor and chair of the chemistry department) from his colleagues (Note: Links have been removed),

More than a year after the chair of Harvard University’s chemistry department was arrested for allegedly hiding his receipt of millions of dollars in research funding from China from his university and the US government, dozens of prominent researchers – including many Nobel Prize winners – are coming to Charles Lieber’s defence. They are calling the US Department of Justice (DOJ) case against him ‘unjust’ and urging the agency to drop it.

Following his January 2020 arrest, Lieber was placed on ‘indefinite’ paid administrative leave. The nanoscience pioneer was indicted in June [2020] on charges of making false statements to federal authorities regarding his participation in China’s Thousand Talents plan – the country’s programme to attract, recruit and cultivate high-level scientific talent from abroad. Lieber faces up to five years in prison and a fine of $250,000 (£179,000) if convicted.

A 1 March [2021] open letter, drafted and coordinated by Harvard chemist Stuart Schreiber, co-founder of the Broad Institute, and professor emeritus Elias Corey, winner of the 1990 chemistry Nobel prize, says Lieber became the target of a ‘tragically misguided government campaign’. The letter refers to Lieber as ‘one of the great scientist of his generation’ and warns such government actions are discouraging US scientists from collaborating with peers in other countries, particularly China. The open letter also notes that Lieber is fighting to salvage his reputation while suffering from incurable lymphoma.

Ferguson goes on to contrast Lieber’s treatment by Harvard to another embattled colleague’s treatment by his home institution (Note: Links have been removed),

Harvard’s treatment of Lieber stands in contrast to how the Massachusetts Institute of Technology (MIT) handled the more recent case of nanotechnologist Gang Chen, who was arrested in January [2021] for failing to report his ties to the Chinese government. MIT agreed to cover his legal fees, and more than 100 faculty members signed a letter to their university’s president that picked apart the DOJ’s allegations against Chen.

I have more details about the case against Lieber (as it was presented at the time) in a January 28, 2020 posting.

As for Professor Chen, I found this MIT statement dated January 14, 2021 (the date of his arrest) and this January 14, 2021 statement from The United States District Attorney’s Office District of Massachusetts.

Concrete collapse and research into durability

I have two items about concrete buildings, one concerns the June 24, 2021 collapse of a 12-storey condominium building in Surfside, close to Miami Beach in Florida. There are at least 20 people dead and, I believe, over 120 are still unaccounted for (July 2, 2021 Associated Press news item on Canadian Broadcasting Corporation news online website).

Miami collapse

Nate Berg’s June 25, 2021 article for Fast Company provides an instructive overview of the building collapse (Note: A link has been removed),

Why the building collapsed is not yet known [emphasis mine]. David Darwin is a professor of civil engineering at the University of Kansas and an expert in reinforced concrete structures, and he says the eventual investigation of the Surfside collapse will explore all the potential causes, ranging from movement in the foundation before the collapse, corrosion in the debris, and excessive cracking in the part of the building that remains standing. “There are all sorts of potential causes of failure,” Darwin says. “At this point, speculation is not helpful for anybody.”

Sometimes I can access the entire article, and at other times, only a few paragraphs; I hope you get access to all of it as it provides a lot of information.

The Surfside news puts this research from Northwestern University (Chicago, Illinois) into much sharper relief than might otherwise be the case. (Further on I have some information about the difference between cement and concrete and how cement leads to concrete.)

Smart cement for more durable roads and cities

Coincidentally, just days before the Miami Beach building collapse, a June 21, 2021 Northwestern University news release (also on EurekAlert), announced research into improving water and fracture resistance in cement,

Forces of nature have been outsmarting the materials we use to build our infrastructure since we started producing them. Ice and snow turn major roads into rubble every year; foundations of houses crack and crumble, in spite of sturdy construction. In addition to the tons of waste produced by broken bits of concrete, each lane-mile of road costs the U.S. approximately $24,000 per year to keep it in good repair.

Engineers tackling this issue with smart materials typically enhance the function of materials by increasing the amount of carbon, but doing so makes materials lose some mechanical performance. By introducing nanoparticles into ordinary cement, Northwestern University researchers have formed a smarter, more durable and highly functional cement.

The research was published today (June 21 [2021]) in the journal Philosophical Transactions of the Royal Society A.

With cement being the most widely consumed material globally and the cement industry accounting for 8% of human-caused greenhouse gas emissions, civil and environmental engineering professor Ange-Therese Akono turned to nanoreinforced cement to look for a solution. Akono, the lead author on the study and an assistant professor in the McCormick School of Engineering, said nanomaterials reduce the carbon footprint of cement composites, but until now, little was known about its impact on fracture behavior.

“The role of nanoparticles in this application has not been understood before now, so this is a major breakthrough,” Akono said. “As a fracture mechanics expert by training, I wanted to understand how to change cement production to enhance the fracture response.”

Traditional fracture testing, in which a series of light beams is cast onto a large block of material, involves lots of time and materials and seldom leads to the discovery of new materials.

By using an innovative method called scratch testing, Akono’s lab efficiently formed predictions on the material’s properties in a fraction of the time. The method tests fracture response by applying a conical probe with increasing vertical force against the surface of microscopic bits of cement. Akono, who developed the novel method during her Ph.D. work, said it requires less material and accelerates the discovery of new ones.

“I was able to look at many different materials at the same time,” Akono said. “My method is applied directly at the micrometer and nanometer scales, which saves a considerable amount of time. And then based on this, we can understand how materials behave, how they crack and ultimately predict their resistance to fracture.”

Predictions formed through scratch tests also allow engineers to make changes to materials that enhance their performance at the larger scale. In the paper, graphene nanoplatelets, a material rapidly gaining popularity in forming smart materials, were used to improve the resistance to fracture of ordinary cement. Incorporating a small amount of the nanomaterial also was shown to improve water transport properties including pore structure and water penetration resistance, with reported relative decreases of 76% and 78%, respectively.

Implications of the study span many fields, including building construction, road maintenance, sensor and generator optimization and structural health monitoring.

By 2050, the United Nations predicts two-thirds of the world population will be concentrated in cities. Given the trend toward urbanization, cement production is expected to skyrocket.

Introducing green concrete that employs lighter, higher-performing cement will reduce its overall carbon footprint by extending maintenance schedules and reducing waste.

Alternately, smart materials allow cities to meet the needs of growing populations in terms of connectivity, energy and multifunctionality. Carbon-based nanomaterials including graphene nanoplatelets are already being considered in the design of smart cement-based sensors for structural health monitoring.

Akono said she’s excited for both follow-ups to the paper in her own lab and the ways her research will influence others. She’s already working on proposals that look into using construction waste to form new concrete and is considering “taking the paper further” by increasing the fraction of nanomaterial that cement contains.

“I want to look at other properties like understanding the long-term performance,” Akono said. “For instance, if you have a building made of carbon-based nanomaterials, how can you predict the resistance in 10, 20 even 40 years?”

The study, “Fracture toughness of one- and two-dimensional nanoreinforced cement via scratch testing,” was supported by the National Science Foundation Division of Civil, Mechanical and Manufacturing Innovation (award number 18929101).

Akono will give a talk on the paper at The Royal Society’s October [2021] meeting, “A Cracking Approach to Inventing Tough New Materials: Fracture Stranger Than Friction,” which will highlight major advances in fracture mechanics from the past century.

I don’t often include these kinds of photos (one or more of the researchers posing (sometimes holding something) for the camera but I love the professor’s first name, Ange-Therese (which means angel in French, I don’t know if she ever uses the French spelling for Thérèse),

Caption: Professor Ange-Therese Akono holds a sample of her smart cement. Credit: Northwestern University

Here’s a link to and a citation for the paper,

Fracture toughness of one- and two-dimensional nanoreinforced cement via scratch testing by Ange-Therese Akono. Philosophical Transactions of the Royal Society A: Mathematical, Physical & Engineering Sciences 2021 379 (2203): 20200288 DOI: 10.1098/rsta.2020.0288 Published June 21, 2021

This paper appears to be open access.

Cement vs. concrete

Andrew Logan’s April 3, 2020 article for MIT (Massachusetts Institute of Technology) News is a very readable explanation of how cement and concrete differ and how they are related,

There’s a lot the average person doesn’t know about concrete. For example, it’s porous; it’s the world’s most-used material after water; and, perhaps most fundamentally, it’s not cement.

Though many use “cement” and “concrete” interchangeably, they actually refer to two different — but related — materials: Concrete is a composite made from several materials, one of which is cement. [emphasis mine]

Cement production begins with limestone, a sedimentary rock. Once quarried, it is mixed with a silica source, such as industrial byproducts slag or fly ash, and gets fired in a kiln at 2,700 degrees Fahrenheit. What comes out of the kiln is called clinker. Cement plants grind clinker down to an extremely fine powder and mix in a few additives. The final result is cement.

“Cement is then brought to sites where it is mixed with water, where it becomes cement paste,” explains Professor Franz-Josef Ulm, faculty director of the MIT Concrete Sustainability Hub (CSHub). “If you add sand to that paste it becomes mortar. And if you add to the mortar large aggregates — stones of a diameter of up to an inch — it becomes concrete.”

Final thoughts

I offer my sympathies to the folks affected by the building collapse and my hopes that research will lead the way to more durable cement and, ultimately, concrete buildings.

Precision targeting of the liver for gene editing

Apparently the magic is in the lipid nanoparticles. A March 1, 2021 news item on Nanowerk announced research into lipid nanoparticles as a means to deliver CRISPR (clustered regularly interspaced short palindromic repeats) to specific organs (Note: A link has been removed),

The genome editing technology CRISPR has emerged as a powerful new tool that can change the way we treat disease. The challenge when altering the genetics of our cells, however, is how to do it safely, effectively, and specifically targeted to the gene, tissue and organ that needs treatment.

Scientists at Tufts University and the Broad Institute of Harvard [University] and MIT [Massachusetts Institute of Technology] have developed unique nanoparticles comprised of lipids — fat molecules — that can package and deliver gene editing machinery specifically to the liver.

In a study published in the Proceedings of the National Academy of Sciences [PNAS] (“Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3”), they have shown that they can use the lipid nanoparticles (LNPs) to efficiently deliver the CRISPR machinery into the liver of mice, resulting in specific genome editing and the reduction of blood cholesterol levels by as much as 57% — a reduction that can last for at least several months with just one shot.

A March 2, 2021 Tufts University news release (also on EurekAlert but published March 1, 2021), which originated the news item, provides greater insight into and technical detail about the research,

The problem of high cholesterol plagues more than 29 million Americans, according to the Centers for Disease Control and Prevention. The condition is complex and can originate from multiple genes as well as nutritional and lifestyle choices, so it is not easy to treat. The Tufts and Broad researchers, however, have modified one gene that could provide a protective effect against elevated cholesterol if it can be shut down by gene editing.

The gene that the researchers focused on codes for the angiopoietin-like 3 enzyme (Angptl3). That enzyme tamps down the activity of other enzymes – lipases – that help break down cholesterol. If researchers can knock out the Angptl3 gene, they can let the lipases do their work and reduce levels of cholesterol in the blood. It turns out that some lucky people have a natural mutation in their Angptl3 gene, leading to consistently low levels of triglycerides and low-density lipoprotein (LDL) cholesterol, commonly called “bad” cholesterol, in their bloodstream without any known clinical downsides.

“If we can replicate that condition by knocking out the angptl3 gene in others, we have a good chance of having a safe and long term solution to high cholesterol,” said Qiaobing Xu, associate professor of biomedical engineering at Tufts’ School of Engineering and corresponding author of the study. “We just have to make sure we deliver the gene editing package specifically to the liver so as not to create unwanted side effects.”

Xu’s team was able to do precisely that in mouse models. After a single injection of lipid nanoparticles packed with mRNA coding for CRISPR-Cas9 and a single-guide RNA targeting Angptl3, they observed a profound reduction in LDL cholesterol by as much as 57% and triglyceride levels by about 29 %, both of which remained at those lowered levels for at least 100 days. The researchers speculate that the effect may last much longer than that, perhaps limited only by the slow turnover of cells in the liver, which can occur over a period of about a year. The reduction of cholesterol and triglycerides is dose dependent, so their levels could be adjusted by injecting fewer or more LNPs in the single shot, the researchers said.

By comparison, an existing, FDA [US Food and Drug Administration]-approved version of CRISPR mRNA-loaded LNPs could only reduce LDL cholesterol by at most 15.7% and triglycerides by 16.3% when it was tested in mice, according to the researchers.

The trick to making a better LNP was in customizing the components – the molecules that come together to form bubbles around the mRNA. The LNPs are made up of long chain lipids that have a charged or polar head that is attracted to water, a carbon chain tail that points toward the middle of the bubble containing the payload, and a chemical linker between them. Also present are polyethylene glycol, and yes, even some cholesterol – which has a normal role in lipid membranes to make them less leaky – to hold their contents better.

The researchers found that the nature and relative ratio of these components appeared to have profound effects on the delivery of mRNA into the liver, so they tested LNPs with many combinations of heads, tails, linkers and ratios among all components for their ability to target liver cells. Because the in vitro potency of an LNP formulation rarely reflects its in vivo performance, they directly evaluated the delivery specificity and efficacy in mice that have a reporter gene in their cells that lights up red when genome editing occurs. Ultimately, they found a CRISPR mRNA-loaded LNP that lit up just the liver in mice, showing that it could specifically and efficiently deliver gene-editing tools into the liver to do their work.

The LNPs were built upon earlier work at Tufts, where Xu and his team developed LNPs with as much as 90% efficiency in delivering mRNA into cells. A unique feature of those nanoparticles was the presence of disulfide bonds between the long lipid chains. Outside the cells, the LNPs form a stable spherical structure that locks in their contents. When they are inside a cell, the environment within breaks the disulfide bonds to disassemble the nanoparticles. The contents are then quickly and efficiently released into the cell. By preventing loss outside the cell, the LNPs can have a much higher yield in delivering their contents.

“CRISPR is one of the most powerful therapeutic tools for the treatment of diseases with a genetic etiology. We have recently seen the first human clinical trail for CRISPR therapy enabled by LNP delivery to be administered systemically to edit genes inside the human body. Our LNP platform developed here holds great potential for clinical translation,” said Min Qiu, post-doctoral researcher in Xu’s lab at Tufts.  “We envision that with this LNP platform in hand, we could now make CRISPR a practical and safe approach to treat a broad spectrum of liver diseases or disorders,” said Zachary Glass, graduate student in the Xu lab. Qiu and Glass are co-first authors of the study.

Here’s a link to and a citation for the paper,

Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3 by Min Qiu, Zachary Glass, Jinjin Chen, Mary Haas, Xin Jin, Xuewei Zhao, Xuehui Rui, Zhongfeng Ye, Yamin Li, Feng Zhang, and Qiaobing Xu. PNAS March 9, 2021 118 (10) e2020401118 DOI: https://doi.org/10.1073/pnas.2020401118

This paper appears to be behind a paywall.

A 3D spider web, a VR (virtual reality) setup, and sonification (music)

Markus Buehler and his musical spider webs are making news again.

Caption: Cross-sectional images (shown in different colors) of a spider web were combined into this 3D image and translated into music. Credit: Isabelle Su and Markus Buehler

The image (so pretty) you see in the above comes from a Markus Buehler presentation that was made at the American Chemical Society (ACS) meeting. ACS Spring 2021 being held online April 5-30, 2021. The image was also shown during a press conference which the ACS has made available for public viewing. More about that later in this posting.

The ACS issued an April 12, 2021 news release (also on EurekAlert), which provides details about Buehler’s latest work on spider webs and music,

Spiders are master builders, expertly weaving strands of silk into intricate 3D webs that serve as the spider’s home and hunting ground. If humans could enter the spider’s world, they could learn about web construction, arachnid behavior and more. Today, scientists report that they have translated the structure of a web into music, which could have applications ranging from better 3D printers to cross-species communication and otherworldly musical compositions.

The researchers will present their results today at the spring meeting of the American Chemical Society (ACS). ACS Spring 2021 is being held online April 5-30 [2021]. Live sessions will be hosted April 5-16, and on-demand and networking content will continue through April 30 [2021]. The meeting features nearly 9,000 presentations on a wide range of science topics.

“The spider lives in an environment of vibrating strings,” says Markus Buehler, Ph.D., the project’s principal investigator, who is presenting the work. “They don’t see very well, so they sense their world through vibrations, which have different frequencies.” Such vibrations occur, for example, when the spider stretches a silk strand during construction, or when the wind or a trapped fly moves the web.

Buehler, who has long been interested in music, wondered if he could extract rhythms and melodies of non-human origin from natural materials, such as spider webs. “Webs could be a new source for musical inspiration that is very different from the usual human experience,” he says. In addition, by experiencing a web through hearing as well as vision, Buehler and colleagues at the Massachusetts Institute of Technology (MIT), together with collaborator Tomás Saraceno at Studio Tomás Saraceno, hoped to gain new insights into the 3D architecture and construction of webs.

With these goals in mind, the researchers scanned a natural spider web with a laser to capture 2D cross-sections and then used computer algorithms to reconstruct the web’s 3D network. The team assigned different frequencies of sound to strands of the web, creating “notes” that they combined in patterns based on the web’s 3D structure to generate melodies. The researchers then created a harp-like instrument and played the spider web music in several live performances around the world.

The team also made a virtual reality setup that allowed people to visually and audibly “enter” the web. “The virtual reality environment is really intriguing because your ears are going to pick up structural features that you might see but not immediately recognize,” Buehler says. “By hearing it and seeing it at the same time, you can really start to understand the environment the spider lives in.”

To gain insights into how spiders build webs, the researchers scanned a web during the construction process, transforming each stage into music with different sounds. “The sounds our harp-like instrument makes change during the process, reflecting the way the spider builds the web,” Buehler says. “So, we can explore the temporal sequence of how the web is being constructed in audible form.” This step-by-step knowledge of how a spider builds a web could help in devising “spider-mimicking” 3D printers that build complex microelectronics. “The spider’s way of ‘printing’ the web is remarkable because no support material is used, as is often needed in current 3D printing methods,” he says.

In other experiments, the researchers explored how the sound of a web changes as it’s exposed to different mechanical forces, such as stretching. “In the virtual reality environment, we can begin to pull the web apart, and when we do that, the tension of the strings and the sound they produce change. At some point, the strands break, and they make a snapping sound,” Buehler says.

The team is also interested in learning how to communicate with spiders in their own language. They recorded web vibrations produced when spiders performed different activities, such as building a web, communicating with other spiders or sending courtship signals. Although the frequencies sounded similar to the human ear, a machine learning algorithm correctly classified the sounds into the different activities. “Now we’re trying to generate synthetic signals to basically speak the language of the spider,” Buehler says. “If we expose them to certain patterns of rhythms or vibrations, can we affect what they do, and can we begin to communicate with them? Those are really exciting ideas.”

You can go here for the April 12, 2021 ‘Making music from spider webs’ ACS press conference’ it runs about 30 mins. and you will hear some ‘spider music’ played.

Getting back to the image and spider webs in general, we are most familiar with orb webs (in the part of Canada where I from if nowhere else), which look like spirals and are 2D. There are several other types of webs some of which are 3D, like tangle webs, also known as cobwebs, funnel webs and more. See this March 18, 2020 article “9 Types of Spider Webs: Identification + Pictures & Spiders” by Zach David on Beyond the Treat for more about spiders and their webs. If you have the time, I recommend reading it.

I’ve been following Buehler’s spider web/music work for close to ten years now; the latest previous posting is an October 23, 2019 posting where you’ll find a link to an application that makes music from proteins (spider webs are made up of proteins; scroll down about 30% of the way; it’s in the 2nd to last line of the quoted text about the embedded video).

Here is a video (2 mins. 17 secs.) of a spider web music performance that Buehler placed on YouTube,

Feb 3, 2021

Markus J. Buehler

Spider’s Canvas/Arachonodrone show excerpt at Palais de Tokyo, Paris, on November 2018. Video by MIT CAST. More videos can be found on www.arachnodrone.com. The performance was commissioned by Studio Tomás Saraceno (STS), in the context of Saraceno’s carte blanche exhibition, ON AIR. Spider’s Canvas/Arachnodrone was performed by Isabelle Su and Ian Hattwick on the spider web instrument, Evan Ziporyn on the EWI (Electronic Wind Instrument), and Christine Southworth on the guitar and EBow (Electronic Bow)

You can find more about the spider web music and Buehler’s collaborators on http://www.arachnodrone.com/,

Spider’s Canvas / Arachnodrone is inspired by the multifaceted work of artist Tomas Saraceno, specifically his work using multiple species of spiders to make sculptural webs. Different species make very different types of webs, ranging not just in size but in design and functionality. Tomas’ own web sculptures are in essence collaborations with the spiders themselves, placing them sequentially over time in the same space, so that the complex, 3-dimensional sculptural web that results is in fact built by several spiders, working together.

Meanwhile, back among the humans at MIT, Isabelle Su, a Course 1 doctoral student in civil engineering, has been focusing on analyzing the structure of single-species spider webs, specifically the ‘tent webs’ of the cyrtophora citricola, a tropical spider of particular interest to her, Tomas, and Professor Markus Buehler. Tomas gave the department a cyrtophora spider, the department gave the spider a space (a small terrarium without glass), and she in turn built a beautiful and complex web. Isabelle then scanned it in 3D and made a virtual model. At the suggestion of Evan Ziporyn and Eran Egozy, she then ported the model into Unity, a VR/game making program, where a ‘player’ can move through it in numerous ways. Evan & Christine Southworth then worked with her on ‘sonifying’ the web and turning it into an interactive virtual instrument, effectively turning the web into a 1700-string resonating instrument, based on the proportional length of each individual piece of silk and their proximity to one another. As we move through the web (currently just with a computer trackpad, but eventually in a VR environment), we create a ‘sonic biome’: complex ‘just intonation’ chords that come in and out of earshot according to which of her strings we are closest to. That part was all done in MAX/MSP, a very flexible high level audio programming environment, which was connected with the virtual environment in Unity. Our new colleague Ian Hattwick joined the team focusing on sound design and spatialization, building an interface that allowed him the sonically ‘sculpt’ the sculpture in real time, changing amplitude, resonance, and other factors. During this performance at Palais de Tokyo, Isabelle toured the web – that’s what the viewer sees – while Ian adjusted sounds, so in essence they were together “playing the web.” Isabelle provides a space (the virtual web) and a specific location within it (by driving through), which is what the viewer sees, from multiple angles, on the 3 scrims. The location has certain acoustic potentialities, and Ian occupies them sonically, just as a real human performer does in a real acoustic space. A rough analogy might be something like wandering through a gothic cathedral or a resonant cave, using your voice or an instrument at different volumes and on different pitches to find sonorous resonances, echoes, etc. Meanwhile, Evan and Christine are improvising with the web instrument, building on Ian’s sound, with Evan on EWI (Electronic Wind Instrument) and Christine on electric guitar with EBow.

For the visuals, Southworth wanted to create the illusion that the performers were actually inside the web. We built a structure covered in sharkstooth scrim, with 3 projectors projecting in and through from 3 sides. Southworth created images using her photographs of local Lexington, MA spider webs mixed with slides of the scan of the web at MIT, and then mixed those images with the projection of the game, creating an interactive replica of Saraceno’s multi-species webs.

If you listen to the press conference, you will hear Buehler talk about practical applications for this work in materials science.

Use kombucha to produce bacterial cellulose

The combination of the US Army, bacterial cellulose, and kombucha seems a little unusual. However, this January 26, 2021 U.S. Army Research Laboratory news release (also on EurekAlert) provides some clues as to how this combination makes sense,

Kombucha tea, a trendy fermented beverage, inspired researchers to develop a new way to generate tough, functional materials using a mixture of bacteria and yeast similar to the kombucha mother used to ferment tea.

With Army funding, using this mixture, also called a SCOBY, or symbiotic culture of bacteria and yeast, engineers at MIT [Massachusetts Institute of Technology] and Imperial College London produced cellulose embedded with enzymes that can perform a variety of functions, such as sensing environmental pollutants and self-healing materials.

The team also showed that they could incorporate yeast directly into the cellulose, creating living materials that could be used to purify water for Soldiers in the field or make smart packaging materials that can detect damage.

“This work provides insights into how synthetic biology approaches can harness the design of biotic-abiotic interfaces with biological organization over multiple length scales,” said Dr. Dawanne Poree, program manager, Army Research Office, an element of the U.S. Army Combat Capabilities Development Command, now known as DEVCOM, Army Research Laboratory. “This is important to the Army as this can lead to new materials with potential applications in microbial fuel cells, sense and respond systems, and self-reporting and self-repairing materials.”

The research, published in Nature Materials was funded by ARO [Army Research Office] and the Army’s Institute for Soldier Nanotechnologies [ISN] at the Massachusetts Institute of Technology. The U.S. Army established the ISN in 2002 as an interdisciplinary research center devoted to dramatically improving the protection, survivability, and mission capabilities of the Soldier and Soldier-supporting platforms and systems.

“We foresee a future where diverse materials could be grown at home or in local production facilities, using biology rather than resource-intensive centralized manufacturing,” said Timothy Lu, an MIT associate professor of electrical engineering and computer science and of biological engineering.

Researchers produced cellulose embedded with enzymes, creating living materials that could be used to purify water for Soldiers in the field or make smart packaging materials that can detect damage. These fermentation factories, which usually contain one species of bacteria and one or more yeast species, produce ethanol, cellulose, and acetic acid that gives kombucha tea its distinctive flavor.

Most of the wild yeast strains used for fermentation are difficult to genetically modify, so the researchers replaced them with a strain of laboratory yeast called Saccharomyces cerevisiae. They combined the yeast with a type of bacteria called Komagataeibacter rhaeticus that their collaborators at Imperial College London had previously isolated from a kombucha mother. This species can produce large quantities of cellulose.

Because the researchers used a laboratory strain of yeast, they could engineer the cells to do any of the things that lab yeast can do, such as producing enzymes that glow in the dark, or sensing pollutants or pathogens in the environment. The yeast can also be programmed so that they can break down pollutants/pathogens after detecting them, which is highly relevant to Army for chem/bio defense applications.

“Our community believes that living materials could provide the most effective sensing of chem/bio warfare agents, especially those of unknown genetics and chemistry,” said Dr. Jim Burgess ISN program manager for ARO.

The bacteria in the culture produced large-scale quantities of tough cellulose that served as a scaffold. The researchers designed their system so that they can control whether the yeast themselves, or just the enzymes that they produce, are incorporated into the cellulose structure. It takes only a few days to grow the material, and if left long enough, it can thicken to occupy a space as large as a bathtub.

“We think this is a good system that is very cheap and very easy to make in very large quantities,” said MIT graduate student and the paper’s lead author, Tzu-Chieh Tang. To demonstrate the potential of their microbe culture, which they call Syn-SCOBY, the researchers created a material incorporating yeast that senses estradiol, which is sometimes found as an environmental pollutant. In another version, they used a strain of yeast that produces a glowing protein called luciferase when exposed to blue light. These yeasts could be swapped out for other strains that detect other pollutants, metals, or pathogens.

The researchers are now looking into using the Syn-SCOBY system for biomedical or food applications. For example, engineering the yeast cells to produce antimicrobials or proteins that could benefit human health.

Here’s a link to and a citation for the paper,

Living materials with programmable functionalities grown from engineered microbial co-cultures by Charlie Gilbert, Tzu-Chieh Tang, Wolfgang Ott, Brandon A. Dorr, William M. Shaw, George L. Sun, Timothy K. Lu & Tom Ellis. Nature Materials (2021) DOI: https://doi.org/10.1038/s41563-020-00857-5 Published: 11 January 2021

This paper is behind a paywall.

Self-assembled molecular nanofibers that are stronger than steel

A January 26, 2021 news item on Nanowerk announces a promising discovery in ‘self-assembly research’ (Note: A link has been removed,

Self-assembly is ubiquitous in the natural world, serving as a route to form organized structures in every living organism. This phenomenon can be seen, for instance, when two strands of DNA — without any external prodding or guidance — join to form a double helix, or when large numbers of molecules combine to create membranes or other vital cellular structures. Everything goes to its rightful place without an unseen builder having to put all the pieces together, one at a time.

For the past couple of decades, scientists and engineers have been following nature’s lead, designing molecules that assemble themselves in water, with the goal of making nanostructures, primarily for biomedical applications such as drug delivery or tissue engineering.

“These small-molecule-based materials tend to degrade rather quickly,” explains Julia Ortony, assistant professor in [Massachusetts Institute of Technology] MIT’s Department of Materials Science and Engineering (DMSE), “and they’re chemically unstable, too. The whole structure falls apart when you remove the water, particularly when any kind of external force is applied.”

She and her team, however, have designed a new class of small molecules that spontaneously assemble into nanoribbons with unprecedented strength, retaining their structure outside of water. The results of this multi-year effort, which could inspire a broad range of applications, were described in Nature Nanotechnology (“Self-assembly of aramid amphiphiles into ultra-stable nanoribbons and aligned nanoribbon threads”) by Ortony and coauthors.

“This seminal work — which yielded anomalous mechanical properties through highly controlled self-assembly — should have a big impact on the field,” asserts Professor Tazuko Aida, deputy director for the RIKEN Center for Emergent Matter Science and professor of chemistry and biotechnology at the University of Tokyo, who was not involved in the research.

A January 26, 2021 MIT news release, which originated the news item, describe the work in more detail,

The material the MIT group constructed — or rather, allowed to construct itself — is modeled after a cell membrane. Its outer part is “hydrophilic,” which means it likes to be in water, whereas its inner part is “hydrophobic,” meaning it tries to avoid water. This configuration, Ortony comments, “provides a driving force for self-assembly,” as the molecules orient themselves to minimize interactions between the hydrophobic regions and water, consequently taking on a nanoscale shape.

The shape, in this case, is conferred by water, and ordinarily the whole structure would collapse when dried. But Ortony and her colleagues came up with a plan to keep that from happening. When molecules are loosely bound together, they move around quickly, analogous to a fluid; as the strength of intermolecular forces increases, motion slows and molecules assume a solid-like state. The idea, Ortony explains, “is to slow molecular motion through small modifications to the individual molecules, which can lead to a collective, and hopefully dramatic, change in the nanostructure’s properties.”

One way of slowing down molecules, notes Ty Christoff-Tempesta, a PhD student and first author of the paper, “is to have them cling to each other more strongly than in biological systems.” That can be accomplished when a dense network of strong hydrogen bonds join the molecules together. “That’s what gives a material like Kevlar — constructed of so-called ‘aramids’ — its chemical stability and strength,” states Christoff-Tempesta.

Ortony’s team incorporated that capability into their design of a molecule that has three main components: an outer portion that likes to interact with water, aramids in the middle for binding, and an inner part that has a strong aversion to water. The researchers tested dozens of molecules meeting these criteria before finding the design that led to long ribbons with nanometer-scale thickness. The authors then measured the nanoribbons’ strength and stiffness to understand the impact of including Kevlar-like interactions between molecules. They discovered that the nanoribbons were unexpectedly sturdy — stronger than steel, in fact. 

This finding led the authors to wonder if the nanoribbons could be bundled to produce stable macroscopic materials. Ortony’s group devised a strategy whereby aligned nanoribbons were pulled into long threads that could be dried and handled. Notably, Ortony’s team showed that the threads could hold 200 times their own weight and have extraordinarily high surface areas — 200 square meters per gram of material. “This high surface-to-mass ratio offers promise for miniaturizing technologies by performing more chemistry with less material,” explains Christoff-Tempesta. To this end, they have already developed nanoribbons whose surfaces are coated with molecules that can pull heavy metals, like lead or arsenic, out of contaminated water. Other efforts in the research group are aimed at using bundled nanoribbons in electronic devices and batteries.

Ortony, for her part, is still amazed that they’ve been able to achieve their original research goal of “tuning the internal state of matter to create exceptionally strong molecular nanostructures.” Things could easily have gone the other way; these materials might have proved to be disorganized, or their structures fragile, like their predecessors, only holding up in water. But, she says, “we were excited to see that our modifications to the molecular structure were indeed amplified by the collective behavior of molecules, creating nanostructures with extremely robust mechanical properties. The next step, figuring out the most important applications, will be exciting.”

Here’s a link to and a citation for the paper,

Self-assembly of aramid amphiphiles into ultra-stable nanoribbons and aligned nanoribbon threads by Ty Christoff-Tempesta, Yukio Cho, Dae-Yoon Kim, Michela Geri, Guillaume Lamour, Andrew J. Lew, Xiaobing Zuo, William R. Lindemann & Julia H. Ortony. Nature Nanotechnology (2021) DOI: https://doi.org/10.1038/s41565-020-00840-w Published: 18 January 2021

This paper is behind a paywall.

mRNA, COVID-19 vaccines, treating genetic diseases before birth, and the scientist who started it all

This post was going to be about new research into fetal therapeutics and mRNA.But, since I’ve been very intrigued by the therapeutic agent, mRNA, which has been a big part of the COVID-19 vaccine story; this seemed like a good opportunity to dive a little more deeply into that topic at the same time.

It’s called messenger ribonucleic acid (mRNA) and until seeing this video I had only the foggiest idea of how it works, which is troubling since at least two COVID-19 vaccines are based on this ‘new’ technology. From a November 10, 2020 article by Damian Garde for STAT,

Garde’s article offers detail about mRNA along with fascinating insight into how science and entreneurship works.

mRNA—it’s in the details, plus, the loneliness of pioneer researchers, a demotion, and squabbles

Garde’s November 10, 2020 article provides some explanation about how mRNA vaccines work and it takes a look at what can happen to pioneering scientists (Note: A link has been removed),

For decades, scientists have dreamed about the seemingly endless possibilities of custom-made messenger RNA, or mRNA.

Researchers understood its role as a recipe book for the body’s trillions of cells, but their efforts to expand the menu have come in fits and starts. The concept: By making precise tweaks to synthetic mRNA and injecting people with it, any cell in the body could be transformed into an on-demand drug factory. [emphasis mine]

But turning scientific promise into medical reality has been more difficult than many assumed. Although relatively easy and quick to produce compared to traditional vaccine-making, no mRNA vaccine or drug has ever won approval [until 2021].

Whether mRNA vaccines succeed or not, their path from a gleam in a scientist’s eye to the brink of government approval has been a tale of personal perseverance, eureka moments in the lab, soaring expectations — and an unprecedented flow of cash into the biotech industry.

Before messenger RNA was a multibillion-dollar idea, it was a scientific backwater. And for the Hungarian-born scientist behind a key mRNA discovery, it was a career dead-end.

Katalin Karikó spent the 1990s collecting rejections. Her work, attempting to harness the power of mRNA to fight disease, was too far-fetched for government grants, corporate funding, and even support from her own colleagues.

It all made sense on paper. In the natural world, the body relies on millions of tiny proteins to keep itself alive and healthy, and it uses mRNA to tell cells which proteins to make. If you could design your own mRNA, you could, in theory, hijack that process and create any protein you might desire — antibodies to vaccinate against infection, enzymes to reverse a rare disease, or growth agents to mend damaged heart tissue.

In 1990, researchers at the University of Wisconsin managed to make it work in mice. Karikó wanted to go further.

The problem, she knew, was that synthetic RNA was notoriously vulnerable to the body’s natural defenses, meaning it would likely be destroyed before reaching its target cells. And, worse, the resulting biological havoc might stir up an immune response that could make the therapy a health risk for some patients.

It was a real obstacle, and still may be, but Karikó was convinced it was one she could work around. Few shared her confidence.

“Every night I was working: grant, grant, grant,” Karikó remembered, referring to her efforts to obtain funding. “And it came back always no, no, no.”

By 1995, after six years on the faculty at the University of Pennsylvania, Karikó got demoted. She had been on the path to full professorship, but with no money coming in to support her work on mRNA, her bosses saw no point in pressing on.

She was back to the lower rungs of the scientific academy.

“Usually, at that point, people just say goodbye and leave because it’s so horrible,” Karikó said.

There’s no opportune time for demotion, but 1995 had already been uncommonly difficult. Karikó had recently endured a cancer scare, and her husband was stuck in Hungary sorting out a visa issue. Now the work to which she’d devoted countless hours was slipping through her fingers.

“I thought of going somewhere else, or doing something else,” Karikó said. “I also thought maybe I’m not good enough, not smart enough. I tried to imagine: Everything is here, and I just have to do better experiments.”

In time, those better experiments came together. After a decade of trial and error, Karikó and her longtime collaborator at Penn — Drew Weissman, an immunologist with a medical degree and Ph.D. from Boston University — discovered a remedy for mRNA’s Achilles’ heel.

The stumbling block, as Karikó’s many grant rejections pointed out, was that injecting synthetic mRNA typically led to that vexing immune response; the body sensed a chemical intruder, and went to war. The solution, Karikó and Weissman discovered, was the biological equivalent of swapping out a tire.

Every strand of mRNA is made up of four molecular building blocks called nucleosides. But in its altered, synthetic form, one of those building blocks, like a misaligned wheel on a car, was throwing everything off by signaling the immune system. So Karikó and Weissman simply subbed it out for a slightly tweaked version, creating a hybrid mRNA that could sneak its way into cells without alerting the body’s defenses.

“That was a key discovery,” said Norbert Pardi, an assistant professor of medicine at Penn and frequent collaborator. “Karikó and Weissman figured out that if you incorporate modified nucleosides into mRNA, you can kill two birds with one stone.”

That discovery, described in a series of scientific papers starting in 2005, largely flew under the radar at first, said Weissman, but it offered absolution to the mRNA researchers who had kept the faith during the technology’s lean years. And it was the starter pistol for the vaccine sprint to come.

Entrepreneurs rush in

Garde’s November 10, 2020 article shifts focus from Karikó, Weissman, and specifics about mRNA to the beginnings of what might be called an entrepreneurial gold rush although it starts sedately,

Derrick Rossi [emphasis mine], a native of Toronto who rooted for the Maple Leafs and sported a soul patch, was a 39-year-old postdoctoral fellow in stem cell biology at Stanford University in 2005 when he read the first paper. Not only did he recognize it as groundbreaking, he now says Karikó and Weissman deserve the Nobel Prize in chemistry.

“If anyone asks me whom to vote for some day down the line, I would put them front and center,” he said. “That fundamental discovery is going to go into medicines that help the world.”

But Rossi didn’t have vaccines on his mind when he set out to build on their findings in 2007 as a new assistant professor at Harvard Medical School running his own lab.

He wondered whether modified messenger RNA might hold the key to obtaining something else researchers desperately wanted: a new source of embryonic stem cells [emphasis mine].

In a feat of biological alchemy, embryonic stem cells can turn into any type of cell in the body. That gives them the potential to treat a dizzying array of conditions, from Parkinson’s disease to spinal cord injuries.

But using those cells for research had created an ethical firestorm because they are harvested from discarded embryos.

Rossi thought he might be able to sidestep the controversy. He would use modified messenger molecules to reprogram adult cells so that they acted like embryonic stem cells.

He asked a postdoctoral fellow in his lab to explore the idea. In 2009, after more than a year of work, the postdoc waved Rossi over to a microscope. Rossi peered through the lens and saw something extraordinary: a plate full of the very cells he had hoped to create.

Rossi excitedly informed his colleague Timothy Springer, another professor at Harvard Medical School and a biotech entrepreneur. Recognizing the commercial potential, Springer contacted Robert Langer, the prolific inventor and biomedical engineering professor at the Massachusetts Institute of Technology.

On a May afternoon in 2010, Rossi and Springer visited Langer at his laboratory in Cambridge. What happened at the two-hour meeting and in the days that followed has become the stuff of legend — and an ego-bruising squabble.

Langer is a towering figure in biotechnology and an expert on drug-delivery technology. At least 400 drug and medical device companies have licensed his patents. His office walls display many of his 250 major awards, including the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers.

As he listened to Rossi describe his use of modified mRNA, Langer recalled, he realized the young professor had discovered something far bigger than a novel way to create stem cells. Cloaking mRNA so it could slip into cells to produce proteins had a staggering number of applications, Langer thought, and might even save millions of lives.

“I think you can do a lot better than that,” Langer recalled telling Rossi, referring to stem cells. “I think you could make new drugs, new vaccines — everything.”

Within several months, Rossi, Langer, Afeyan [Noubar Afeyan, venture capitalist, founded and runs Flagship Ventures], and another physician-researcher at Harvard formed the firm Moderna — a new word combining modified and RNA.

Springer was the first investor to pledge money, Rossi said. In a 2012 Moderna news release, Afeyan said the firm’s “promise rivals that of the earliest biotechnology companies over 30 years ago — adding an entirely new drug category to the pharmaceutical arsenal.”

But although Moderna has made each of the founders hundreds of millions of dollars — even before the company had produced a single product — Rossi’s account is marked by bitterness. In interviews with the [Boston] Globe in October [2020], he accused Langer and Afeyan of propagating a condescending myth that he didn’t understand his discovery’s full potential until they pointed it out to him.

Garde goes on to explain how BioNTech came into the mRNA picture and contrasts the two companies’ approaches to biotechnology as a business. It seems BioNTech has not cashed in the same way as has Moderna. (For some insight into who’s making money from COVID-19 check out Giacomo Tognini’s December 23, 2020 article (Meet The 50 Doctors, Scientists And Healthcare Entrepreneurs Who Became Pandemic Billionaires In 2020) for Forbes.)

Garde ends his November 10, 2020 article on a mildly cautionary note,

“You have all these odd clinical and pathological changes caused by this novel bat coronavirus [emphasis mine], and you’re about to meet it with all of these vaccines with which you have no experience,” said Paul Offit, an infectious disease expert at Children’s Hospital of Philadelphia and an authority on vaccines.

What happened to Katalin Karikó?

Matthew Rosza’s January 25, 2021 article about Karikó and her pioneering work features an answer to my question and some advice,

“I want young people to feel — if my example, because I was demoted, rejected, terminated, I was even subject for deportation one point — [that] if they just pursue their thing, my example helps them to wear rejection as a badge,” Karikó, who today is a senior vice president at BioNTech RNA Pharmaceuticals, told Salon last month when discussing her story. “‘Okay, well, I was rejected. I know. Katalin was rejected and still [succeeded] at the end.’ So if it helps them, then it helps them.”

Despite her demotion, Karikó continued with her work and, along with a fellow immunologist named Dr. Drew Weissman, penned a series of influential articles starting in 2005. These articles argued that mRNA vaccines would not be neutralized by the human immune system as long as there were specific modifications to nucleosides, a compound commonly found in RNA.

By 2013, Karikó’s work had sufficiently impressed experts that she left the University of Pennsylvania for BioNTech RNA Pharmaceuticals.

Karikó tells Salon that the experience taught her one important lesson: In life there will be people who, for various reasons, will try to hold you back, and you can’t let them get you down.

“People that are in power, they can help you or block you,” Karikó told Salon. “And sometimes people select to make your life miserable. And now they cannot be happy with me because now they know that, ‘Oh, you know, we had the confrontation and…’ But I don’t spend too much time on these things.”

Before moving onto the genetic research which prompted this posting, I have an answer to the following questions:

Could an mRNA vaccine affect your DNA (deoxyribonucleic acid) and how do mRNA vaccines differ from the traditional ones?

No, DNA is not affected by the COVID-19 mRNA vaccines, according to a January 5, 2021 article by Jason Murdock for Newsweek,

The type of vaccines used against COVID-19 do not interact with or alter human genetic code, also known as DNA, scientists say.

In traditional vaccines, a piece of a virus, known as an “antigen,” would be injected into the body to force the immune system to make antibodies to fight off future infection. But mRNA-based methods do not use a live virus, and cannot give someone COVID.

Instead, mRNA vaccines give cells the instructions to make a “spike” protein also found on the surface of the virus that causes COVID. The body kickstarts its immune response by creating the antibodies needed to combat those specific virus proteins.

Once the spike protein is created, the cell breaks down the instructions provided by the mRNA molecule, leaving the human immune system prepared to combat infection. The mRNA vaccines are not a medicine—nor a cure—but a preventative measure.

Gavi, a vaccine alliance partnered with the World Health Organization (WHO), has said that mRNA instructions will become degraded in approximately 72 hours.

It says mRNA strands are “chemical intermediaries” between DNA in our chromosomes and the “cellular machinery that produces the proteins we need to function.”

But crucially, while mRNA vaccines will give the human body the blueprints on how to assemble proteins, the alliance said in a fact-sheet last month that “mRNA isn’t the same as DNA, and it can’t combine with our DNA to change our genetic code.”

It explained: “Some viruses like HIV can integrate their genetic material into the DNA of their hosts, but this isn’t true of all viruses… mRNA vaccines don’t carry these enzymes, so there is no risk of the genetic material they contain altering our DNA.”

The [US] Centers for Disease Control and Prevention (CDC) says on its website that mRNA vaccines that are rolling out don’t “interact with our DNA in any way,” and “mRNA never enters the nucleus of the cell, which is where our DNA (genetic material) is kept.”

Therapeutic fetal mRNA treatment

Rossi’s work on mRNA and embryonic stem cells bears a relationship of sorts to this work focusing on prebirth therapeutics. (From a January 13, 2021 news item on Nanowerk), Note: A link has been removed,

Researchers at Children’s Hospital of Philadelphia and the School of Engineering and Applied Science at the University of Pennsylvania have identified ionizable lipid nanoparticles that could be used to deliver mRNA as part of fetal therapy.

The proof-of-concept study, published in Science Advances (“Ionizable Lipid Nanoparticles for In Utero mRNA Delivery”), engineered and screened a number of lipid nanoparticle formulations for targeting mouse fetal organs and has laid the groundwork for testing potential therapies to treat genetic diseases before birth.

A January 13, 2021 Children’s Hospital of Philadelphia (CHOP) news release (also on EurekAlert), which originated the news item, delves further into the research,

“This is an important first step in identifying nonviral mediated approaches for delivering cutting-edge therapies before birth,” said co-senior author William H. Peranteau, MD, an attending surgeon in the Division of General, Thoracic and Fetal Surgery and the Adzick-McCausland Distinguished Chair in Fetal and Pediatric Surgery at CHOP. “These lipid nanoparticles may provide a platform for in utero mRNA delivery, which would be used in therapies like fetal protein replacement and gene editing.”

Recent advances in DNA sequencing technology and prenatal diagnostics have made it possible to diagnose many genetic diseases before birth. Some of these diseases are treated by protein or enzyme replacement therapies after birth, but by then, some of the damaging effects of the disease have taken hold. Thus, applying therapies while the patient is still in the womb has the potential to be more effective for some conditions. The small fetal size allows for maximal therapeutic dosing, and the immature fetal immune system may be more tolerant of replacement therapy.

Of the potential vehicles for introducing therapeutic protein replacement, mRNA is distinct from other nucleic acids, such as DNA, because it does not need to enter the nucleus and can use the body’s own machinery to produce the desired proteins. Currently, the common methods of nucleic acid delivery include viral vectors and nonviral approaches. Although viral vectors may be well-suited to gene therapy, they come with the potential risk of unwanted integration of the transgene or parts of the viral vector in the recipient genome. Thus, there is an important need to develop safe and effective nonviral nucleic acid delivery technologies to treat prenatal diseases.

In order to identify potential nonviral delivery systems for therapeutic mRNA, the researchers engineered a library of lipid nanoparticles, small particles less than 100 nanometers in size that effectively enter cells in mouse fetal recipients. Each lipid nanoparticle formulation was used to encapsulate mRNA, which was administered to mouse fetuses. The researchers found that several of the lipid nanoparticles enabled functional mRNA delivery to fetal livers and that some of those lipid nanoparticles also delivered mRNA to the fetal lungs and intestines. They also assessed the lipid nanoparticles for toxicity and found them to be as safe or safer than existing formulations.

Having identified the lipid nanoparticles that were able to accumulate within fetal livers, lungs, and intestines with the highest efficiency and safety, the researchers also tested therapeutic potential of those designs by using them to deliver erythropoietin (EPO) mRNA, as the EPO protein is easily trackable. They found that EPO mRNA delivery to liver cells in mouse fetuses resulted in elevated levels of EPO protein in the fetal circulation, providing a model for protein replacement therapy via the liver using these lipid nanoparticles.

“A central challenge in the field of gene therapy is the delivery of nucleic acids to target cells and tissues, without causing side effects in healthy tissue. This is difficult to achieve in adult animals and humans, which have been studied extensively. Much less is known in terms of what is required to achieve in utero nucleic acid delivery,” said Mitchell. “We are very excited by the initial results of our lipid nanoparticle technology to deliver mRNA in utero in safe and effective manner, which could open new avenues for lipid nanoparticles and mRNA therapeutics to treat diseases before birth.”

Here’s a link to and a citation for the paper,

Ionizable lipid nanoparticles for in utero mRNA delivery by Rachel S. Riley, Meghana V. Kashyap, Margaret M. Billingsley, Brandon White, Mohamad-Gabriel Alameh, Sourav K. Bose, Philip W. Zoltick, Hiaying Li, Rui Zhang, Andrew Y. Cheng, Drew Weissman, William H. Peranteau, Michael J. Mitchell. Science Advances 13 Jan 2021: Vol. 7, no. 3, eaba1028 DOI: 10.1126/sciadv.aba1028

This paper appears to be open access. BTW, I noticed Drew Weissman’s name as one of the paper’s authors and remembered him as one of the first to recognize Karikó’s pioneering work. I imagine that when he co-authored papers with Karikó he was risking his reputation.

Funny how a despised field of research has sparked a ‘gold rush’ for research and for riches, yes?.